Modulation of Progesterone Receptor Activity Treated with Conjugated Estrogen and Bazedoxifene by Huh, Eunna
Modulation of Progesterone Receptor Activity  
Treated with Conjugated Estrogens and Bazedoxifene 
 Huh, Eunna, State University of New York at Fredonia, Class of 2014 
Carolyn L Smith, ph.D. Department of Molecular & Cell Biology, Baylor College of Medicine 
 
When Women reach menopause, they face dramatic changes which can include severe 
symptoms such as night sweats, vaginal dryness, depression, hot flashes, and osteoporosis. These 
symptoms have been treated by hormone therapy consisting of estrogen and progesterone, but 
this combined therapy is associated with an increase in the risk of breast cancer; thus another 
approach for control of menopausal symptoms is desirable. Selective Estrogen Receptor 
Modulators (SERM) are used for reducing breast tumor as well as increasing bone mineral 
density (BMD). Clinical studies showed that a combination of SERM and one or more estrogen 
can increase BMD, and relieve menopausal symptoms. This combination is referred as Tissue 
Selective Estrogen Complex (TSEC).  As a TSEC, the combination of bazedoxifene and 
conjugated estrogens (CE) inhibited MCF-7 cell growth in vitro. 
I tested the level of progesterone receptor (PR) activity was assessed by GRE-e1b-luc 
reporter gene which generates luciferase when it is activated. It was optimized the concentration 
of PR and the level of progesterone in dose response experiments. In HeLa cells transfected only 
with PR, and the luciferase reporter gene, the PR activity was not stimulated by CE, BAZ, and  
BAZ/CE, whereas showed modest inhibitory effect. On the other hand, in progesterone-treated 
cells expressing both PR and ER (estrogen receptor), BAZ and BAZ/CE stimulated PR activity 
while CE inhibited the receptor’s transcriptional activity.  
 
